Verona Pharma shareholders approve $10B acquisition by Merck at $107/ADS

Verona Pharma plc

Shareholders voted 99.49% in value in favor of the scheme of arrangement.
Court sanction hearing scheduled for October 6, 2025; expected closing October 7, 2025.
Total transaction value approx. $10 billion, representing $107 per American Depositary Share.
99.51% of votes cast in favor of special resolution; 81.19% in favor of advisory executive compensation vote.

item 5.07item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.